News/Events

Kinex Completes Largest Private Placement Equity Raise in its History to Support the Company’s Global Manufacturing Strategy Monday, May 18th, 2015

Kinex Pharmaceuticals announced today the successful completion of an oversubscribed private placement of equity which was limited to strategic investors. The round was led by world renowned Chinese technology entrepreneur, co-Founder, Chairman and CEO of Tencent Holdings Ltd., Mr. Huateng Ma (“Pony” Ma). Read more>

Hanmi Pharmaceuticals to Assign the Rights of the Indian Territory to Kinex as Part of the Orascovery Program Strategic Plan Monday, March 9th, 2015

Kinex Pharmaceuticals and Hanmi Pharmaceutical Co., Ltd. are pleased to announce the execution of an agreement for Kinex Pharmaceuticals to lead the development of the Orascovery program in India. The addition of this territory is part of the strategic plan to support Kinex and Hanmi’s joint effort to execute a global regulatory strategy. This also strengthens the existing agreement forged with Hanmi in December of 2011. With this agreement, Hanmi has granted to Kinex Pharmaceuticals the rights to develop and commercialize all products derived from the Orascovery program for all indications globally apart from Korea and Japan. Read more>

Kinex Pharmaceuticals Licenses Patents from Hong Kong Polytechnic University Friday, February 13th, 2015

Hong Kong Feb 13, 2015 – Kinex Pharmaceuticals today announces the exclusive licensing of global rights of three patents from The Hong Kong Polytechnic University and McGill University. These three patents covered the inventions by Professor Larry Chow and Professor William Chan including novel new chemical compounds that have nanomolar potency against a molecular target named Breast Cancer Resistance Protein (BCRP). BCRP is a protein pump known to pump drugs, including anticancer drugs, from cancer cells that can lead to drug resistance; and also to pump drugs back into gastrointestinal tract, which prevent some useful drugs to be delivered to their target. Read more>

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-391 Ointment for Actinic Keratosis in a Phase 1 Clinical Study Tuesday, January 20th, 2015

Kinex Pharmaceuticals announced today that the first actinic keratosis patient has been dosed with KX2-391 ointment in Austin, Texas. Read more>

Kinex Pharmaceuticals Announces First Patient Dosed with KX2-361 in a Phase 1 Clinical Study Wednesday, December 24th, 2014

Kinex Pharmaceuticals announced today that the first patient has been dosed with KX2-361 at Roswell Park Cancer Institute. Read more>